查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864772

巨细胞病毒检测市场按产品、检测类型、应用、最终用户和检体类型划分－2025-2032年全球预测

Cytomegalovirus Tests Market by Product, Test Type, Application, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，巨细胞病毒检测市场将成长至 11.9201 亿美元，复合年增长率为 7.25%。

关键市场统计数据
基准年 2024 6.8078亿美元
预计年份：2025年 7.3124亿美元
预测年份 2032 1,192,010,000 美元
复合年增长率 (%) 7.25%

临床因素、诊断重点和操作考量之间的策略整合塑造了当代巨细胞病毒检测和推广。

随着诊断技术和诊疗路径的不断发展，巨细胞病毒(CMV) 检测的临床和公共卫生重要性日益凸显。早期准确识别 CMV 感染仍然是新生儿护理、移植患者管理、捐赠者筛检和产前风险控制的基础。随着精准诊断和快速照护现场方案的日益普及，来自临床、实验室、研究和商业领域的相关人员必须将技术能力、应用场景优先级和监管要求清晰地整合起来，以指导投资和营运决策。

本概要摘要了目前影响鉅细胞病毒 (CMV) 检测普及的驱动因素和限制因素，重点阐述了检测性能特征与实际临床需求之间的相互作用。它着重介绍了检测方法的进步、监管和报销趋势的影响，以及决定在不同终端用户环境下检测普及的营运因素。透过阐述不同检体类型和临床应用领域的诊断价值提案，本概述为深入分析变革性转变、政策影响、细分领域洞察以及为寻求优化诊断组合和临床路径的决策者提供的实用建议奠定了基础。

分子诊断和照护现场技术的进步、监管机构对检验的重视以及检体的灵活性，正在如何重塑巨细胞病毒检测的临床应用？

鉅细胞病毒 (CMV) 检测领域正经历多重变革，这些变革的驱动力包括技术成熟、临床重点的转变以及对快速、有效检测结果日益增长的需求。分子扩增技术在灵敏度和通量方面取得了显着进步，使得在多种检体基质中实现早期检测成为可能，并支持超越传统血清学检测的更广泛的临床应用场景。同时，照护现场方法和简化的抗原检测方式正在融合，以便更贴近患者使用，从而降低了门诊和新生儿监护病房及时诊断的门槛，而这些场所对即时做出治疗决策至关重要。

监管路径和实验室认证标准也在重塑产品的设计和部署。製造商优先考虑可靠的检验数据、简化的使用者工作流程以及与实验室资讯系统的兼容性，以满足医院和参考实验室的要求。定量结果与定性评估的结合，推动了对能够支持监测和治疗决策的检测方法的需求，尤其是在移植和周产期护理领域。同时，检体类型的灵活性（从全血扩展到尿液、唾液和组织检体）正在拓宽检测的可能性，并实现微创诊断策略。

这些变化进一步受到医疗保健系统优先事项的强化，这些优先事项强调全面的诊断管理、经济高效的筛检通讯协定以及更快的检测结果出炉时间。随着技术的融合，成功的产品将在分析性能、易用性、监管合应对力和明确的临床效用之间取得平衡。最终将形成一个重视互通性、循证声明以及能够预见从急诊护理到社区医疗保健等不同终端用户需求的开发策略的诊断环境。

美国近期加征关税对巨细胞病毒检测诊断供应链、筹资策略和製造商采购韧性的影响

美国近期实施的关税政策为全球诊断零件和设备的供应链带来了新的复杂性。进口试剂、仪器零件及相关耗材的关税增加了製造商和检测实验室的到岸成本，促使他们重新评估筹资策略和库存管理。对于依赖跨境供应链的企业而言，这些措施增加了其寻求供应来源多元化和近岸外包方案的必要性，以降低关税相关成本波动带来的风险。

为此，製造商和经销商正在考虑多项措施，包括重新谈判供应商合约、增加库存缓衝以及加快低关税地区替代供应商的资格认证。实验室和医疗系统被要求评估总体拥有成本，不仅包括单位成本，还包括物流、海关延误和潜在的停机风险。采购部门正与临床相关人员密切合作，确定关键检测的优先顺序，并制定产品导入计划，以在控制财务限制的同时，维持临床工作的连续性。

政策主导的成本压力也影响企业在本地製造投资和产品组合的策略决策。一些公司正在对设备设计进行模组化，以便在免税地区组装和零件采购；而另一些公司则在寻求许可和契约製造协议，以维持市场进入。因此，竞争优势越来越依赖供应链的韧性以及在波动的贸易环境中维持服务水准协定的能力。对于采购负责人和规划人员而言，关税环境凸显了基于情境的采购规划以及保持灵活合约的重要性，这些合约能够适应分销和生产的变化，同时又不影响临床运作。

全面的細項分析揭示了产品模式、检测结果、临床应用、终端使用者工作流程和检体基质如何决定诊断价值和市场接受度。

透过分析产品、检测类型、应用领域、最终用户和检体类型，可以揭示鉅细胞病毒 (CMV) 诊断的价值和需求如何随着临床环境和技术特性而变化。按产品类型划分，这些诊断包括抗原检测、核酸增幅检查和血清学检测。抗原检测方法可分为萤光和侧向层析法，两者在速度和灵敏度之间各有优劣。萤光法通常用于寻求更高分析灵敏度的中心实验室，而侧向层析抗原检测则满足了快速床边筛检的需求。核酸增幅检查包括数位聚合酵素链锁反应(dPCR)、等温扩增和即时聚合酵素链锁反应(即时PCR)。数位 PCR 可提供绝对定量，适用于病毒量监测，而等温扩增法则简化了仪器操作并可快速获得结果。然而，由于即时PCR在灵敏度、通量和监管亲和性方面达到了平衡，因此仍然是领先的检测方法。血清学检测涵盖化学冷光免疫检测、酵素免疫分析法和侧向流动免疫检测等形式，提供有关宿主免疫反应的补充信息，并在筛检和流行病学监测中发挥核心作用。

按检测类型划分，定性检测在初步筛检和二元诊断决策中仍然至关重要，而定量检测在监测、风险分层和指导治疗管理方面发挥越来越重要的作用。基于应用领域的区分錶明，诊断应用、供体筛检、产前检测和一般人群筛检对检测特性（例如检测限、检体通量和易操作性）的要求各不相同。最终使用者的特征进一步细分了优先事项：诊所和医院强调快速提供结果和易于整合到临床工作流程中，诊断实验室优先考虑高通量自动化和资料管理，而研究机构则专注于检测的灵活性、分析灵敏度和与下游分析的兼容性。

检体类型（唾液、组织、尿液、全血）的多样性为非侵入性检测途径提供了可能，但也给检测方法开发人员带来了技术挑战，即如何检验不同检体基质中检测性能的可比较性。尿液和唾液的采集方法非侵入性，适用于新生儿和门诊筛检；而组织和全血则可能用于需要明确诊断或高灵敏度的应用。基于这些考量，成功的产品策略应将分析优势与目标使用者的实际操作需求以及每项检测旨在解决的临床问题相结合。

诊断环境和基础设施的区域差异导致了不同的招募路径

区域趋势影响着技术应用、报销机制、实验室基础设施和临床指南，从而为每个地区创造了独特的策略要务。在美洲，诊断生态系统的特点是实验室网路完善、分子平台应用广泛，以及强调对高风险族群进行早期检测的临床指南。这些系统重视那些具有临床效用、扩充性以及与电子健康记录相容性的检测方法，同时也要求强大的供应链和合规性。

欧洲、中东和非洲地区（EMEA）法规环境和医疗基础设施的差异，导致了不同的技术应用路径。一些市场优先考虑使用高通量分子平台进行集中检测，而其他市场则更重视适用于资源有限环境且经济高效的分散式筛检解决方案。在这些地区营运的製造商必须制定灵活的监管策略和分级产品方案，以满足支付方期望和实验室能力的差异。

亚太地区正迅速采用创新诊断技术，其临床需求和采购模式也呈现多样化的特性。对公共卫生筛检计画的投入不断增加、三级医疗服务的覆盖范围不断扩大以及对本地製造能力的重视，正在塑造该地区的商业性模式。在多个司法管辖区，简化的监管审批流程和积极的公私合营正在加速技术的应用，而供应链在地化的努力也正在影响合约签订和定价趋势。在所有地区，成功的关键在于：根据当地实际情况产生证据、与临床意见领袖密切合作，以及建立能够适应当地分销实际情况的物流模式。

现有平台公司、专业创新企业和通路合作伙伴之间的竞争动态和策略行动正在影响检测套组的可及性和临床检验。

鉅细胞病毒 (CMV) 检测领域的竞争格局呈现出平台型製造商、专业检测开发人员和专注于特定临床应用的创新企业并存的态势。成熟的诊断公司凭藉其丰富的产品系列、良好的监管记录和全球分销网络，提供从高通量检测系统到照护现场设备等一系列整合解决方案。为了维繫客户忠诚度并满足医院和参考实验室的需求，这些现有企业正加强对临床检验研究、跨平台相容性和生命週期服务协议的投入。

专业检测开发人员通常透过技术创新脱颖而出，例如提高灵敏度、简化分散式检查流程以及采用专有化学技术来加快检测结果的出具速度。技术先驱与大型经销商之间的合作已成为新型检测方法拓展应用范围的常见途径，既能利用现有销售管道和监管方面的专业知识，又能涵盖更广泛的临床环境。专注于数位化增强和样本到结果平台的新兴参与企业正在重塑人们对定量性能和操作简便性的预期。

在竞争激烈的市场环境中，服务和支援模式对采购决策的影响日益显着。买家重视能够提供安装、培训、持续技术支援和完善的品质保证系统的供应商。随着企业快速提升自身能力并将产品蓝图与临床需求讯号相契合，与临床中心签订共同开发契约、建立OEM伙伴关係以及进行有针对性的收购等策略措施也变得越来越普遍。对于关注竞争的相关人员，关键观点企业如何将技术主张转化为检验的临床结果，如何部署可扩展的商业模式，以及如何在各种政策条件下维持供应的连续性。

业界经营团队可采取切实可行的优先行动，以增强临床信心、韧性和巨细胞病毒诊断解决方案的采用率

产业领导者可以采取果断行动，增强临床对鉅细胞病毒 (CMV) 检测的信心，加速其普及应用，并建立稳健的供应链和商业模式。优先进行强有力的临床检验研究，以证明其在预期用途的效用，将有助于增强支付方和医疗服务提供者的信心。使产品设计与目标终端使用者的实际情况相符（例如，最大限度地减少诊所的操作时间，确保诊断实验室的自动化和高通量），将有助于降低推广应用的障碍，并促进其融入临床工作流程。

投资于供应链韧性至关重要。製造商应透过多元化采购、探索区域製造伙伴关係以及设计可在多个司法管辖区组装的产品，来降低关税风险和物流中断的影响。与临床意见领袖和公共卫生机构合作，产生符合指南的证据，将有助于将其纳入筛检和监测通讯协定。此外，企业应考虑弹性价格设定和服务捆绑，其中应包含考虑买方整体拥有成本的因素，例如试剂稳定性、仪器运作保证和软体互通性。

最后，建构能够实现诊断和临床管理一体化解决方案的伙伴关係，例如将定量病毒载量报告与病患监测平台整合，可以为终端用户创造差异化价值。实施这些措施需要明确的优先顺序、研发、监管和商业团队之间的跨职能协作，以及对证据产生和客户支援基础设施的持续投入。

一种透明且可重复的研究途径，结合了严谨的二手证据审查、与关键相关人员的访谈以及基于情境的检验。

本研究采用实证方法，结合系统性的文献综述和质性访谈，以确保研究结果的平衡性和可重复性。文献回顾涵盖同侪审查的临床文献、监管指南文件和技术白皮书，旨在梳理检测方法的性能特征、建议的临床工作流程和检验标准。定性访谈则包括对临床医生、实验室主任、采购经理和技术开发人员的结构化访谈，以收集有关技术应用驱动因素、营运限制和未满足需求的第一手资讯。

我们应用了一个分析框架，整合了细分维度和跨区域洞察，以确保技术评估立足于临床适用性和实验室实际情况。透过交叉比对设备规格、监管核准和临床结果研究，三角验证技术检验论点。情境分析用于探索供应链中断和政策变化，而对访谈回应的定性编码则识别出与易用性、证据预期和服务需求相关的反覆出现的主题。

所有研究结果均经过内部同侪审查和跨部门检验，以提高研究的稳健性并减少偏差。调查方法强调资讯来源的透明度和分析过程的可重复性，使相关人员能够评估我们结论的依据，并根据自身内部情况调整框架。

综合结论强调，检验的创新、营运韧性和实证实施是有效巨细胞病毒诊断策略的支柱。

鉅细胞病毒 (CMV) 诊断处于临床需求、技术创新和营运要求三者交汇点。分子扩增和即时抗原照护现场技术的进步正在拓展 CMV 检测的应用情境和案例，尤其是在新生儿、移植患者和孕妇群体中，及时识别 CMV 可显着影响治疗结果。同时，日益严格的监管、供应链限制和区域差异迫使研发人员和采用者采取灵活且基于实证医学的策略，优先考虑临床效用和服务连续性。

决策者应优先考虑产品开发和采购，重点关注其在改善患者管理方面的显着疗效、与现有工作流程的便捷整合以及抵御政策和物流干扰的能力。这将确保相关人员对诊断技术的投资能够带来可衡量的临床效益和永续的商业性回报。最终，这将形成一个奖励成熟创新、实用操作以及协作式证据生成和传播方法的局面。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大多重PCR检测的应用范围，此检测可同时检测多种病毒病原体，包括鉅细胞病毒（CMV）。
  • 新生儿护理环境中对快速、照护现场的鉅细胞病毒 (CMV) 诊断的需求日益增长，以便能够快速应对。
  • 整合次世代定序技术，提供全面的鉅细胞病毒基因组分析，用于抗药性监测。
  • 美国食品药物管理局 (FDA) 已核准多种高灵敏度免疫检测，用于早期检测婴儿先天性巨细胞病毒感染。
  • 北美和欧洲先天性鉅细胞病毒新生儿筛检计画的扩展推动了检测数量的成长。
  • 成本压力正在推动全球参考实验室开发自动化、高通量 CMV 检测平台。
  • 诊断公司与医疗机构建立策略联盟，扩大移植患者鉅细胞病毒筛检

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章巨细胞病毒检测市场（依产品划分）

  • 抗原检测
    • 萤光
    • 横向流动化验
  • 核酸增幅检查
    • 数位聚合酵素链锁反应
    • 等温扩增
    • 即时聚合酵素链锁反应
  • 血清学检测
    • 化学冷光免疫检测
    • 酵素免疫分析法
    • 侧向流动免疫检测

第九章巨细胞病毒检测市场（依检测方法划分）

  • 定性测试
  • 定量测试

第十章巨细胞病毒检测市场（依应用划分）

  • 诊断
  • 捐赠者筛检
  • 产前检查
  • 筛检

第十一章巨细胞病毒检测市场（依最终用户划分）

  • 诊所
  • 诊断实验室
  • 医院
  • 研究所

第十二章巨细胞病毒检测市场（依检体类型划分）

  • 唾液
  • 组织
  • 尿
  • 全血

第十三章巨细胞病毒检测市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章巨细胞病毒检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国巨细胞病毒检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Qiagen NV
    • bioMerieux SA
    • Hologic, Inc.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Becton, Dickinson and Company
    • PerkinElmer, Inc.
Product Code: MRR-6B0EA07975A5

The Cytomegalovirus Tests Market is projected to grow by USD 1,192.01 million at a CAGR of 7.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 680.78 million
Estimated Year [2025] USD 731.24 million
Forecast Year [2032] USD 1,192.01 million
CAGR (%) 7.25%

A strategic synthesis of clinical drivers, diagnostic priorities, and operational considerations shaping contemporary cytomegalovirus testing and adoption

The clinical and public health implications of cytomegalovirus (CMV) testing have intensified as diagnostic technologies and care pathways evolve. Early and accurate identification of CMV infection remains a cornerstone of neonatal care, transplant patient management, donor screening, and prenatal risk mitigation. With growing emphasis on precision diagnostics and rapid point-of-care solutions, stakeholders across clinical, laboratory, research, and commercial domains require a clear synthesis of technological capabilities, use-case priorities, and regulatory expectations to guide investment and operational decisions.

This executive overview synthesizes current drivers and constraints shaping CMV testing adoption, emphasizing the interplay between assay performance characteristics and real-world clinical requirements. It highlights advances in assay modalities, the implications of regulatory and reimbursement trends, and the operational considerations that determine adoption in diverse end-user settings. By clarifying the diagnostic value proposition across sample types and clinical applications, this introduction sets the stage for deeper analysis of transformative shifts, policy impacts, segmentation-specific insights, and practical recommendations for decision-makers seeking to optimize diagnostic portfolios and clinical pathways.

How advances in molecular and point-of-care diagnostics, regulatory emphasis on validation, and sample flexibility are reshaping clinical adoption of cytomegalovirus testing

The CMV testing landscape is undergoing multiple transformative shifts driven by technological maturation, changing clinical priorities, and evolving expectations for rapid, actionable results. Molecular amplification techniques have advanced in sensitivity and throughput, enabling earlier detection in diverse sample matrices and supporting a broader set of clinical scenarios beyond traditional serology. Concurrently, point-of-care modalities and simplified antigen detection formats are converging toward near-patient use, lowering the threshold for timely diagnosis in outpatient clinics and neonatal wards where immediate therapeutic decisions are critical.

Regulatory pathways and laboratory accreditation standards are also reshaping product design and deployment. Manufacturers are prioritizing robust validation data, streamlined user workflows, and compatibility with laboratory information systems to meet hospital and reference laboratory requirements. Integration of quantitative readouts alongside qualitative determinations is increasing demand for assays that can support monitoring and therapeutic decision-making, particularly in transplant medicine and prenatal care. Meanwhile, sample type flexibility-expanding beyond whole blood to include urine, saliva, and tissue specimens-has broadened testing prospects and enabled less invasive diagnostic strategies.

These shifts are reinforced by health system priorities that place a premium on diagnostic stewardship, cost-effective screening protocols, and reduced time-to-result. As technologies converge, successful products will be those that balance analytical performance with usability, regulatory readiness, and clear clinical utility. The cumulative effect is a diagnostic environment that rewards interoperability, evidence-based claims, and development strategies that anticipate diverse end-user needs across acute care and community settings.

Implications of recent United States tariff measures on diagnostic supply chains, procurement strategies, and manufacturer sourcing resilience across cytomegalovirus testing

Recent tariff policies enacted by the United States have introduced an additional layer of complexity to the global supply chain for diagnostic components and instruments. Tariffs on imported reagents, instrument parts, and related consumables can increase landed costs for manufacturers and lab operators, prompting reassessment of sourcing strategies and inventory management. For organizations that rely on cross-border supply chains, these measures have heightened the need for supply diversification and nearshoring options to mitigate exposure to duty-related cost volatility.

In response, manufacturers and distributors have explored multiple mitigations including renegotiating supplier contracts, increasing inventory buffers, and accelerating qualification of alternative vendors in low-tariff jurisdictions. Laboratories and health systems have been compelled to evaluate total cost of ownership rather than unit price alone, factoring in logistics, customs delays, and potential downtime risks. Procurement departments are coordinating more closely with clinical stakeholders to prioritize critical assays and to sequence product rollouts in a manner that preserves clinical continuity while managing fiscal constraints.

Policy-driven cost pressures have also influenced strategic decisions around local manufacturing investment and product configuration. Some firms have opted to modularize instrument design to allow assembly or component sourcing in tariff-exempt locations, while others have pursued licensing or contract manufacturing arrangements to preserve market access. As a result, competitive differentiation is increasingly tied to supply chain resilience and the ability to maintain service level agreements under shifting trade conditions. For buyers and planners, the tariff environment underscores the importance of conducting scenario-based procurement planning and maintaining flexible contracts that can accommodate distribution or production changes without compromising clinical operations.

Comprehensive segmentation analysis revealing how product modality, test output, clinical application, end-user workflows, and sample matrices determine diagnostic value and adoption

Deconstructing CMV diagnostics by product, test type, application, end user, and sample type reveals how value and demand vary across clinical contexts and technology attributes. By product, the landscape includes antigen detection tests, nucleic acid amplification tests, and serological assays. Antigen detection formats differentiate by immunofluorescence and lateral flow approaches, each catering to different speed and sensitivity trade-offs; immunofluorescence assays typically serve centralized labs seeking higher analytical sensitivity while lateral flow antigen tests address rapid near-patient screening needs. Nucleic acid amplification encompasses digital polymerase chain reaction, isothermal amplification techniques, and real-time polymerase chain reaction; digital PCR offers absolute quantification useful for monitoring viral load, isothermal methods facilitate simplified instrumentation and rapid turnaround, and real-time PCR continues to be the workhorse for its balance of sensitivity, throughput, and regulatory familiarity. Serological assays, spanning chemiluminescent immunoassay, enzyme-linked immunosorbent assay, and lateral flow immunoassay formats, provide complementary information on host immune response and are central to screening and epidemiologic surveillance.

When viewed by test type, qualitative assays remain important for initial screening and binary diagnostic decisions, while quantitative assays increasingly inform monitoring, risk stratification, and therapeutic management. Application-driven differentiation shows that diagnostic use, donor screening, prenatal testing, and general population screening each place distinct demands on assay attributes such as limit of detection, sample throughput, and ease of use. End-user dynamics further stratify priorities: clinics and hospitals emphasize rapid turnaround and ease of integration into clinical workflows, diagnostic laboratories prioritize high-throughput automation and data management, and research institutes focus on assay flexibility, analytical sensitivity, and compatibility with downstream analyses.

Sample type variation-saliva, tissue, urine, and whole blood-creates opportunities for less invasive testing pathways as well as technical challenges for assay developers in validating performance equivalently across matrices. Urine and saliva offer noninvasive collection suited to neonatal and outpatient screening, whereas tissue and whole blood may be required for definitive diagnosis or for applications demanding high sensitivity. Across these axes, successful product strategies are those that align analytical strengths with the operational realities of target users and the clinical questions each assay seeks to answer.

Regional diagnostic landscapes and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated adoption pathways

Regional dynamics shape technology adoption, reimbursement practices, laboratory infrastructure, and clinical guidelines, creating distinct strategic imperatives across geographies. In the Americas, diagnostic ecosystems are characterized by well-established laboratory networks, adoption of molecular platforms, and clinical guidelines that favor early detection in high-risk populations. These systems reward assays that demonstrate clinical utility, scalability, and compatibility with electronic health records, while also demanding resilient supply chains and regulatory compliance.

In Europe, the Middle East & Africa region, heterogeneity in regulatory environments and healthcare infrastructure leads to varied adoption pathways. Some markets prioritize centralized testing with high-throughput molecular platforms, whereas others emphasize cost-effective, decentralized screening solutions that can function in lower-resource settings. Manufacturers pursuing these geographies must design flexible regulatory strategies and tiered product offerings to address divergent payer expectations and laboratory capabilities.

The Asia-Pacific region exhibits rapid uptake of innovative diagnostic technologies alongside diverse clinical needs and procurement models. Growing investments in public health screening programs, expanding access to tertiary care, and a strong emphasis on local manufacturing capacity shape commercial approaches. In several jurisdictions, expedited regulatory pathways and active public-private partnerships accelerate adoption, while supply chain localization efforts influence contractual and pricing dynamics. Across all regions, success depends on tailored evidence-generation, close engagement with clinical opinion leaders, and logistical models that account for regional distribution realities.

Competitive dynamics and strategic behaviors among platform incumbents, specialized innovators, and channel partners shaping assay availability and clinical validation

Competitive activity in the CMV testing arena reflects a mix of platform-focused manufacturers, specialized assay developers, and emerging innovators targeting niche clinical applications. Established diagnostic firms tend to compete on portfolio breadth, regulatory track record, and global distribution networks, offering integrated solutions that span high-throughput laboratory systems to point-of-care instrumentation. These incumbents invest in clinical validation studies, cross-platform compatibility, and lifecycle service agreements to maintain customer lock-in and to support hospital and reference laboratory requirements.

Specialized assay developers often differentiate through technical innovation such as enhanced sensitivity, simplified workflows for decentralized testing, or proprietary chemistries that reduce time-to-result. Partnerships between technology pioneers and larger distributors have become a common path to scale, enabling novel assays to reach broader clinical settings while leveraging established sales channels and regulatory expertise. New entrants focused on digital amplification methods or sample-to-answer platforms are reshaping expectations for quantitative performance and operational simplicity.

Across competitive dynamics, service and support models increasingly influence procurement decisions. Buyers value vendors that can provide installation, training, ongoing technical support, and robust quality assurance programs. Strategic behaviors such as co-development agreements with clinical centers, OEM partnerships, and targeted acquisitions are prevalent as firms seek to bolster capabilities quickly and to align product roadmaps with clinical demand signals. For stakeholders monitoring competitiveness, the critical lens is on how firms translate technical claims into validated clinical outcomes, deploy scalable commercial models, and maintain supply continuity under varied policy conditions.

Practical and prioritized actions for industry executives to enhance clinical credibility, resilience, and adoption of cytomegalovirus diagnostic solutions

Industry leaders can act decisively to capture clinical trust, accelerate adoption, and build resilient supply and commercial models in CMV testing. Prioritizing robust clinical validation studies that demonstrate actionable utility across intended applications will strengthen payer and provider confidence. Aligning product design with the operational realities of target end users-such as minimizing hands-on time for clinics or ensuring automation and throughput for diagnostic laboratories-will reduce barriers to adoption and support integration into clinical workflows.

Investing in supply chain resilience is essential; manufacturers should diversify sourcing, consider regional manufacturing partnerships, and design products that can be assembled across multiple jurisdictions to mitigate tariff exposure and logistical disruption. Collaborating with clinical thought leaders and public health authorities to generate guideline-aligned evidence will facilitate inclusion in screening and monitoring protocols. Additionally, companies should evaluate flexible pricing and service bundles that reflect total cost of ownership considerations for buyers, including reagent stability, instrument uptime guarantees, and software interoperability.

Finally, fostering partnerships that enable combined diagnostic and clinical management solutions-such as integrating quantitative viral load reporting with patient monitoring platforms-can create differentiated value for end users. Executing on these actions will require clear prioritization, cross-functional coordination between R&D, regulatory, and commercial teams, and disciplined investment in evidence generation and customer support infrastructure.

Transparent, reproducible research approach combining rigorous secondary evidence review with primary stakeholder interviews and scenario-based validation

This research utilized an evidence-driven methodology combining systematic secondary literature review with primary qualitative interviews to ensure balanced and reproducible findings. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers to map assay performance characteristics, recommended clinical workflows, and validation standards. Primary research included structured interviews with clinicians, laboratory directors, procurement managers, and technology developers to capture firsthand perspectives on adoption drivers, operational constraints, and unmet needs.

Analytical frameworks were applied to synthesize insights across segmentation axes and geographies, ensuring that technology assessments were grounded in clinical applicability and laboratory realities. Triangulation techniques validated claims by cross-referencing instrument specifications, regulatory approvals, and clinical outcome studies. Scenario analysis was used to explore supply chain disruptions and policy shifts, while qualitative coding of interview responses identified recurring themes related to usability, evidence expectations, and service requirements.

All findings were subjected to internal peer review and cross-functional validation to enhance robustness and to reduce bias. The methodology emphasized transparency in source attribution and reproducibility of analytic steps, enabling stakeholders to assess the evidentiary basis for conclusions and to adapt frameworks for internal use.

Consolidated conclusions emphasizing validated innovation, operational resilience, and evidence-driven adoption as the pillars for effective cytomegalovirus diagnostic strategies

CMV diagnostics occupy a dynamic intersection of clinical need, technological innovation, and operational imperatives. Advances in molecular amplification and point-of-care antigen detection are expanding the settings and use cases where timely CMV identification can materially influence outcomes for neonates, transplant recipients, and pregnant patients. At the same time, regulatory rigor, supply chain constraints, and regional heterogeneity demand that developers and adopters pursue evidence-driven, flexible strategies that prioritize clinical utility and service continuity.

Decision-makers should orient product development and procurement around demonstrable improvements in patient management, ease of integration into existing workflows, and resilience against policy- or logistics-driven disruptions. By doing so, stakeholders can ensure that investments in diagnostics translate into measurable clinical benefits and sustainable commercial returns. The net effect is a landscape that rewards validated innovation, operational pragmatism, and collaborative approaches to evidence generation and distribution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of multiplex PCR assays enabling simultaneous detection of multiple viral pathogens including CMV
  • 5.2. Rising demand for rapid point of care CMV diagnostics to facilitate timely management in neonatal care settings
  • 5.3. Integration of next generation sequencing techniques to provide comprehensive CMV genome analysis for drug resistance monitoring
  • 5.4. Emerging FDA clearances of highly sensitive immunoassays for early detection of congenital cytomegalovirus infections in infants
  • 5.5. Growing implementation of newborn screening programs for congenital CMV in North America and Europe driving test volumes
  • 5.6. Cost pressure leading to development of automated high throughput CMV testing platforms in reference laboratories worldwide
  • 5.7. Strategic collaborations between diagnostic companies and healthcare providers to expand CMV screening in transplant patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cytomegalovirus Tests Market, by Product

  • 8.1. Antigen Detection Test
    • 8.1.1. Immunofluorescence Assay
    • 8.1.2. Lateral Flow Assay
  • 8.2. Nucleic Acid Amplification Test
    • 8.2.1. Digital Polymerase Chain Reaction
    • 8.2.2. Isothermal Amplification
    • 8.2.3. Real Time Polymerase Chain Reaction
  • 8.3. Serological Assay
    • 8.3.1. Chemiluminescent Immunoassay
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Lateral Flow Immunoassay

9. Cytomegalovirus Tests Market, by Test Type

  • 9.1. Qualitative
  • 9.2. Quantitative

10. Cytomegalovirus Tests Market, by Application

  • 10.1. Diagnostic
  • 10.2. Donor Screening
  • 10.3. Prenatal Testing
  • 10.4. Screening

11. Cytomegalovirus Tests Market, by End User

  • 11.1. Clinic
  • 11.2. Diagnostic Laboratory
  • 11.3. Hospital
  • 11.4. Research Institute

12. Cytomegalovirus Tests Market, by Sample Type

  • 12.1. Saliva
  • 12.2. Tissue
  • 12.3. Urine
  • 12.4. Whole Blood

13. Cytomegalovirus Tests Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cytomegalovirus Tests Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cytomegalovirus Tests Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Qiagen N.V.
    • 16.3.4. bioMerieux SA
    • 16.3.5. Hologic, Inc.
    • 16.3.6. Siemens Healthineers AG
    • 16.3.7. Thermo Fisher Scientific Inc.
    • 16.3.8. Danaher Corporation
    • 16.3.9. Becton, Dickinson and Company
    • 16.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGEN DETECTION TEST, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL ASSAY, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MIL